ArticleMolecular cancer therapeutics2010

Identification of predictive markers of response to the MEK1/2 inhibitor selumetinib (AZD6244) in K-ras-mutated colorectal cancer.

John J Tentler et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.